Persistent Asset Partners Ltd Buys 1,708 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Persistent Asset Partners Ltd grew its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 7.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,038 shares of the company’s stock after purchasing an additional 1,708 shares during the quarter. Persistent Asset Partners Ltd’s holdings in Immunocore were worth $754,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IMCR. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after acquiring an additional 1,268 shares during the period. Checkpoint Capital L.P. acquired a new stake in Immunocore during the 1st quarter worth approximately $267,000. Banque Transatlantique SA bought a new stake in Immunocore in the 1st quarter valued at $278,000. State of New Jersey Common Pension Fund D acquired a new position in Immunocore in the 2nd quarter valued at $292,000. Finally, Fox Run Management L.L.C. bought a new position in Immunocore during the 2nd quarter worth $372,000. 84.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on IMCR shares. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Wednesday, October 22nd. Wells Fargo & Company assumed coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 target price on the stock. Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Wednesday, October 8th. Finally, Guggenheim began coverage on Immunocore in a research note on Thursday, September 18th. They set a “neutral” rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Insider Transactions at Immunocore

In related news, insider David M. Berman sold 22,532 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Immunocore Price Performance

Shares of IMCR stock opened at $35.95 on Friday. The business has a fifty day simple moving average of $33.92 and a 200 day simple moving average of $33.36. The company has a market cap of $1.81 billion, a P/E ratio of -63.07 and a beta of 0.78. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $39.33.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.32. The firm had revenue of $135.80 million during the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 earnings per share. On average, sell-side analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.